# Tapinarof for Cutaneous Lupus Erythematosus

> **NCT06661213** · EARLY_PHASE1 · ENROLLING_BY_INVITATION · sponsor: **Northwestern University** · enrollment: 10 (estimated)

## Conditions studied

- Cutaneous Lupus Erythematosus

## Interventions

- **DRUG:** Tapinarof

## Key facts

- **NCT ID:** NCT06661213
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-04-03
- **Primary completion:** 2027-11
- **Final completion:** 2027-11
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06661213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06661213, "Tapinarof for Cutaneous Lupus Erythematosus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06661213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*